1. Stanford University School of Medicine Division of Immunology & Rheumatology. The Health Assessment Questionnaire. Available from: http://www.chcr.brown.edu/pcoc/ehaqdescrscoringhaq372.pdf. [Accessed November 16, 2012]
2. The National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9/introduction. [Accessed March 31, 2014].
3. A review of studies mapping (or cross walking) non-preferences based measures of health to generic preference-based measures;Brazier;Eur J Health Econ,2010
4. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments;Longworth;Value Health,2013
5. Stevenson MD, Archer R, Tosh J. et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying anti-rheumatic drugs and after the failure of conventional disease-modifying anti-rheumatic drugs only: systematic review and economic evaluation. Sheffield, UK: University of Sheffield, 2013.